MoonLake Immunotherapeutics (MLTX) Free Cash Flow Growth (3y) (2024 - 2026)
MoonLake Immunotherapeutics (MLTX) Free Cash Flow Growth (3y) (2024 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,380.63 Bn | 66,380.34 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,910.39 Bn | 1,910.33 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 470.95 Bn | 466.16 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 69.92 Bn | 61.16 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.76 Bn | 50.58 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 31.42% |
| 10 | MoonLake Immunotherapeutics | 1.41 Bn | 1.05 Bn | - | -94.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -94.39% |
| Dec 31, 2025 | -71.79% |
| Sep 30, 2025 | -68.25% |
| Jun 30, 2025 | -37.97% |
| Mar 31, 2025 | -39.04% |
| Dec 31, 2024 | -11.36% |
| Sep 30, 2024 | -132.13% |
| Jun 30, 2024 | -2.90% |
| Mar 31, 2024 | -417.60% |